Pröthɛt kanthɛr ɛ jɛn in rɛwdɛ kä kanthɛr tin ŋuan kä wutni̱ rɛy ɣɔaa kɛɛliw, kɛ pek mi̱ ca car i̱ 1,276 million kä nɛy tin pay tuɔk tin ca la̱t kɛ rɛy 2018, min nyooth 7.1% kä nɛy diaal tin tekɛ kanthɛr kä wutni̱.
Kä pek li̱eth kɛ kui̱ pröthɛt kancer bä ɛ mi̱ di̱i̱t, kɛ pek li̱eth mi̱ ca pekdɛ car i̱ 37,005 rɛy ɣɔaa kɛɛliw kɛ ruɔ̱n 2018.
Duŋdɛ ɣöö, nämbäri̱ li̱eth te dääk ɛlɔ̱ŋ kɛ gua̱th in te kɛ jɛ, kɛ Wɛthɛrɛn Aprika min te kɛ gua̱a̱th in dhieecdiɛn mi̱ di̱t ɛlɔ̱ŋ kɛ nämbäri̱ li̱eth kɛ kancer pröthɛta rɛy ɣɔaa, kɛnɛ Nigeria min te kɛ pek nath in di̱i̱t ɛlɔ̱ŋ kɛnɛ kuakni̱ rɛy rööl ɛmɛ.
Rɛy Nigeria, pröthɛt kancer ɛ jɛn min la tuɔk ɛlɔ̱ŋ kä ɛ jɛn kancer in näk naath ɛlɔ̱ŋ kä wutni̱, kɛ pek mi̱ ca car i̱ 32.8 kä nɛy tin tekɛ jɛ kɛnɛ 16.3 li̱w kä wutni̱ 100,000.
Nɛmɛ ɛ mi̱ läny nämbäri̱ li̱eth kä Nɔth Amëri̱ka.
Mi̱ ci̱ juey jɔɔc kɛ jɔak, kä ci̱ kuak ti̱ tɔt thi̱n kɛ kui̱i̱ kä ɣöö ba jɛ ŋa̱c, kɛnɛ ɣöö ci̱ pek in ca gɔ̱a̱r piny kɛnɛ pek in ca lat kɛ kui̱i̱dɛ wä piny ɛ kɛn tin jakɛ nämbäri̱ li̱eth kä Nigeria kä di̱t ɛlɔ̱ŋ.
Rɛy United States, pröthɛt kancer ɛ jɛn in rɛwdɛ in di̱tni̱ jɛn kä li̱w nath kɛ kancer kä wutni̱, kɛ pek wutni̱ ti̱ 40 000 li̱w kɛ juey ɛmɛ kɛ ruɔ̱n.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Lät kɛ kui̱i̱ jua̱thni̱']
['Ɛn wɛbthaay ɛmɛ ca la̱th lät kɛ kui̱ ŋi̱i̱cä kɛnɛ läri kä /cɛ lot ni ɣöö ba ji̱ moc kɛ luäk ki̱mä kiɛ lät ti̱ gööl.']
['Lät kɛ läri tin ca ŋun /ca kɛ bi̱ lät kɛ ɣöö ba jua̱th jek kiɛ ba kɛ ciɛŋ, kä nɛy tin görkɛ luäk ki̱mädiɛn kärɔ̱ ba kɛ thiec kä ki̱m mi̱ tekɛ luäk ki̱mä.']
['Guic ɛ gɔaa ɛn ɣöö ɛn neural net min jak luɔc kä thie̱cni̱, /cɛ thuɔ̱k ɛlɔ̱ŋ mi̱ ci̱ ben kä nämbäri̱ tin te thi̱n. cetkɛ pek nath tin ca jek kɛ juey mi̱ rɛlrɔ.']
['Ni ciaŋ go̱ri ruac kä ki̱mdu kiɛ ram in kɔ̱ŋ mi ŋäc luäk pua̱a̱ny kɛ kui̱ jua̱thdu. /Cu ruac ki̱mdu car kiɛ jääny kɛ go̱ri kɛ kui̱ kä mi ci kuɛn kä wɛbthaay ɛmɛ. Mi caari jɛ ɛn ɣöö deri tekɛ juey mi go̱o̱ri luäk, cɔl 911 kiɛ wër guäth in thia̱k kɛ ji kɛ pɛ̈th. /Thilɛ maar kam ki̱m kɛnɛ juey mi bi̱ tuɔɔk kɛ kui̱ kä wɛbthaay ɛmɛ kiɛ la̱tdɛ. /Ci̱ BioMedLib kiɛ la̱a̱tkɛ, kiɛ ram in gɔ̱a̱r kɛ kui̱ kä wɛbthaay ɛmɛ, bi̱ ruac lat, kiɛ bi̱ ruac lat, kɛ kui̱ läri tin ca ka̱m raar rɛydɛ kiɛ la̱tdɛ.']
['Lät kɛ: ŋuɔ̱t']
['Ɛn Digital Millennium Copyright Act 1998, 17 U.S.C. § 512 (ɛ DMCA) ɛ ŋuɔ̱t mi̱ ŋun ji̱ cuŋni̱ tin ŋääth kɛn ɣöö ci̱ ŋɔaani̱ tin te kä intɛrnɛt ŋuɔ̱tkiɛn to̱l kɛ kui̱ ŋuɔ̱tni̱ cuŋni̱ tin te kä U.S.']
['Mi ca ji̱ ŋäth kɛ thuɔ̱k ɛn ɣöö tëëkɛ mi̱ ca gɔ̱r kiɛ mi̱ ca ka̱m ji̱ rɛy wɛbthaayäda kiɛ lät tin kɔ̱ŋ tin ci̱ ŋuɔ̱t tin ca gɔ̱r ya̱r, ji̱n (kiɛ ram in lät kɛ kui̱du) deri̱ kɔ jäk kä warɛgak mi̱ bi̱ ji̱ thiec ɛn ɣöö ba min ca gɔ̱r kiɛ min ca gɔ̱r woc, kiɛ ba duɔ̱ɔ̱r la̱t kɛ ɣöö bi̱ ji̱ cop thi̱n.']
['Kɛn läri̱ ba kɛ jäk kɛ wargak ɛ la i̱thtäm (guic ni̱ gua̱th in ci̱ i̱thtäm in ca gɔ̱r "Kɔntak" kɛ kui̱ i̱thtäm in ci̱ jäk).']
['DMCA go̱o̱rɛ ɣöö bi̱ ji̱n warɛgakdu lat kɛ kui̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä mat thi̱n kɛ läär ti̱ti̱: (1) latdɛ kɛ kui̱i̱ la̱t in ca gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä min ca lar i̱ ca gɛr; (2) latdɛ kɛ kui̱i̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛnɛ läär ti̱ ro̱ŋ kɛ ɣöö bi̱ kɔn kɛ jek; (3) läri̱ kɛ kui̱i̱ kä min dëë ji̱ luäk kɛ jek, amäni̱ ci̱ötdu, nämbärɛ kä tin ci̱ ji̱ luäk kɛ jek, kɛnɛ emaildu; (4) latdu kɛ ɣöö ci̱ ji̱n ɛ ŋa̱c ɛn ɣöö min ca gɔ̱r kɛ kui̱i̱ kä tin ca lar /ci̱kɛ bi̱ lät kɛ luäkdɛ ɛ gua̱n ŋuɔ̱tni̱ gɔ̱rä, kiɛ ɛ la̱tdɛ, kiɛ kɛ luäk ŋuɔ̱tni̱; ']
['(5) mi ci ji gɔr piny kɛ kuic kä ɣöö bi ji ruac kɛ thuɔ̱k, ɛn ɣöö läri tin ca gɔr ɛ thuɔ̱k kä te ji kɛ lua̱ŋ kɛ ɣöö bi yiöw tin ca gɔr piny tin ca lar ɛ ji̱n ka̱m raar;']
['kɛnɛ (6) mi̱ ca gɔ̱r piny ɛ gua̱n ŋuɔ̱tni̱ kiɛ ram mi̱ tekɛ lua̱ŋ kɛ lät kɛ kui̱dɛ.']
['Mi /kenɛ läri tin ca lat nhial diaal mat thi̱n dɔ̱ŋ derɛ ku lɛ wɔ̱ jɔ̱ɔ̱r kɛ lätni̱ kɛ kɛ.']
['Röm kɛ jɛ']
['Thiecɛ kɔ kɛ email kɛ thiecni kiɛ cär.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Kɛ kui̱']
['BiöMedLib lät kɛ kɔmpi̱e̱tɛri̱ tin lät kärɔ̱ (algorithmi̱ni̱ tin ŋi̱e̱e̱e̱c kɛ makanɛ) kɛ ɣöö ba thie̱e̱cni̱ kɛnɛ luɔcdiɛn kulɛ jiek.']
['Kɔn cua tok kɛ mi̱lli̱ön 35 kä baömedikal publi̱kecin PubMed/Medline. Kä bä, webpage duŋ RefinedWeb.']
